News

AB-Therapeutics participates in the 10th Venture Capital Forum NEOTEC

AB-Therapeutics, located at the UAB Research Park, will have the opportunity to meet investors and secure funding for the development of new drugs for the treatment of lung cancer and pancreatic cancer.

The 10 th NEOTEC Venture Capital Forum is a forum where investors and technology companies in funding rounds meet. AB-Therapeutics has been one of the 15 companies selected to participate in this forum, where they will have the opportunity to present their project to potential investors.


AB-Therapeutics is seeking investors for its first round of funding. 85% of the funds will be invested in the preclinical and clinical development of drug candidates to treat lung cancer and pancreatic cancer, through outsourcing to contract research organizationa (CRO). Only 15% of the costs will be allocated to overhead and human resources.

The spin-off  has a new therapeutic approach for cancer of the lung and pancreas, Multitarget Lipid Signaling, which alters the dynamics of multiple proteins in the cell membrane and has a much lower toxicity compared to classical chemotherapy.

NEOTEC Venture Capital Forum will be held on November 10 in La Rioja, organized by the Center for Industrial Technological Development (CDTI), the Economic Development Agency of La Rioja and RedOTRI, and collaboration, among others, ACC1Ó and the Association of Technology Parks of Spain (APTE).

LATEST NEWS

05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG